Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer

Exclusion criteria

• 2. Subjects must have adequate organ function as defined in the following table (Table 2). Specimens must be collected within 10 days prior to the start of study treatment.
• . Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within the last 2 weeks of the screening test. Participants may be on a stable dose of erythropoietin (≥ approximately 3 months).
• . Serum creatinine and creatinine clearance (CrCl) should be interpreted and calculated per institutional standard.
• . Pregnant, breastfeeding, or expecting to conceive within the projected duration of the study, starting with the screening visit through 3 months after the last dose of trial treatment.
• . If a WOCBP has a positive urine pregnancy test within 72 hours prior to the start of treatment that cannot be confirmed as negative, a serum pregnancy test will be required (see Appendix 1).
• . Participants must have recovered from all AEs due to previous therapies to ≤ Grade 1 or baseline. Participants with ≤ Grade 2 neuropathy, alopecia, or other non-relevant AEs may be deemed eligible at the discretion of the PI. If a participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.
• . Has received prior radiotherapy within 2 weeks of the start of the study intervention.
• . Has received a live vaccine within 30 days prior to the first dose of study drug.